These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 31756610)

  • 1. Intravenous immunoglobulins for the prevention of postpartum relapses in multiple sclerosis.
    Horvat Ledinek A; Brecl Jakob G; Jerše J; Ruška B; Pavičić T; Gabelić T; Barun B; Adamec I; Rot U; Šega Jazbec S; Krbot Skorić M; Habek M
    Mult Scler Relat Disord; 2020 Feb; 38():101519. PubMed ID: 31756610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis.
    Achiron A; Kishner I; Dolev M; Stern Y; Dulitzky M; Schiff E; Achiron R
    J Neurol; 2004 Sep; 251(9):1133-7. PubMed ID: 15372259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of postpartum intravenous immunoglobulins on the relapse rate among patients with multiple sclerosis.
    Brandt-Wouters E; Gerlach OH; Hupperts RM
    Int J Gynaecol Obstet; 2016 Aug; 134(2):194-6. PubMed ID: 27177509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postpartum Treatment With Immunoglobulin Does Not Prevent Relapses of Multiple Sclerosis in the Mother.
    Fragoso YD; Adoni T; Alves-Leon SV; Azambuja ND; Barreira AA; Brooks JB; Carneiro DS; Carvalho MJ; Claudino R; Comini-Frota ER; Domingues RB; Finkelsztejn A; Gama PD; Giacomo MC; Gomes S; Goncalves MV; Grzesiuk AK; Kaimen-Maciel DR; Mendes MF; Morales NM; Morales RR; Muniz A; Papais-Alvarenga RM; Parolin MK; Ribeiro SB; Ruocco HH; Salgado PR; Siquineli F; Souza DB; Tosta ED; Vasconcelos CC; Almeida SM; Bernardes DF; Castro SN; Gama RA; Gomide FA; Finkelzstejn J; Lopes J; Lourenco FH; Lourenco GA; Oliveira CL; Oliveira FT; Oliveira LF; Patroclo CB; Pereira WL; Safanelli J; Sahdo AM; Saldanha PC; Shinzato YF; Souza JM; Zani DE
    Health Care Women Int; 2015; 36(10):1072-80. PubMed ID: 25187102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria.
    Bsteh G; Algrang L; Hegen H; Auer M; Wurth S; Di Pauli F; Deisenhammer F; Berger T
    Mult Scler; 2020 Jan; 26(1):69-78. PubMed ID: 30507345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis.
    Haas J; Hommes OR
    Mult Scler; 2007 Aug; 13(7):900-8. PubMed ID: 17881400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pregnancy and multiple sclerosis: a 2-year experience.
    Orvieto R; Achiron R; Rotstein Z; Noy S; Bar-Hava I; Achiron A
    Eur J Obstet Gynecol Reprod Biol; 1999 Feb; 82(2):191-4. PubMed ID: 10206414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulin treatment in multiple sclerosis: A prospective, rater-blinded analysis of relapse rates during pregnancy and the postnatal period.
    Winkelmann A; Rommer PS; Hecker M; Zettl UK
    CNS Neurosci Ther; 2019 Jan; 25(1):78-85. PubMed ID: 29858532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregnancy in Multiple Sclerosis: A Portuguese cohort study.
    Jesus-Ribeiro J; Correia I; Martins AI; Fonseca M; Marques I; Batista S; Nunes C; Macário C; Almeida MC; Sousa L
    Mult Scler Relat Disord; 2017 Oct; 17():63-68. PubMed ID: 29055477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosis.
    Dudesek A; Zettl UK
    J Neurol; 2006 Sep; 253 Suppl 5():V50-8. PubMed ID: 16998754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
    Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis--results of a retrospective multicenter observational study over five years.
    Haas J; Maas-Enriquez M; Hartung HP
    Mult Scler; 2005 Oct; 11(5):562-7. PubMed ID: 16193894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties.
    Bayry J; Hartung HP; Kaveri SV
    Trends Pharmacol Sci; 2015 Jul; 36(7):419-21. PubMed ID: 26003802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis.
    Boz C; Terzi M; Özer B; Turkoglu R; Karabudak R; Efendi H; Soysal A; Sevim S; Altintas A; Kurne A; Akçalı A; Akman G; Yüceyar N; Balcı BP; Ekmekci Ö; Karahan SZ; Demirkıran M; Altunrende B; Turan ÖF; Gökçen GözübatıkÇelik ; Kale N; Köseoğlu M; Ozakbas S
    Mult Scler Relat Disord; 2019 Nov; 36():101376. PubMed ID: 31473488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies.
    Haas J; Jeffery D; Silva D; Meier DP; Meinert R; Cohen J; Hartung HP
    Mult Scler Relat Disord; 2019 Nov; 36():101335. PubMed ID: 31557679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
    Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapses and obstetric outcomes in women with multiple sclerosis planning pregnancy.
    Berenguer-Ruiz L; Gimenez-Martinez J; Palazón-Bru A; Sempere AP
    J Neurol; 2019 Oct; 266(10):2512-2517. PubMed ID: 31256279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting therapeutic efficacy of intravenous immunoglobulin (IVIG) in individual patients with relapsing remitting multiple sclerosis (RRMS) by functional genomics.
    Berger T; Jacobi C; Haas J; Ransmayr G; Guger M; Zettl UK; Di Pauli F; Taumberger B; Wietek S; Meuer S; Reindl M; Giese T
    J Neuroimmunol; 2014 Dec; 277(1-2):145-52. PubMed ID: 25454729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
    Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
    BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis.
    Vukusic S; Durand-Dubief F; Benoit A; Marignier R; Frangoulis B; Confavreux C
    Mult Scler; 2015 Jun; 21(7):953-5. PubMed ID: 25305253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.